AstraZeneca’s Imfinzi gets EU nod for use in bladder cancer treatment
The approval is supported by findings from the NIAGARA Phase III trial, published in The New England Journal of Medicine.
Biocon Biologics receives EC approval for Denosumab biosimilars
Brii Bio, Joincare sign licensing deal for BRII-693 in Greater China
Alembic acquires Utility Therapeutics to bolster antibacterial portfolio
NICE approves new drug for advanced bowel cancer patients in England and Wales
Dizal’s Zegfrovy wins FDA approval for targeted NSCLC treatment
Analysis
View MoreThe ultimate hub for fine and speciality chemicals
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery